UBS AG Reiterates “GBX 1,600” Price Target for GlaxoSmithKline plc (GSK)
UBS AG set a GBX 1,600 ($20.84) price objective on GlaxoSmithKline plc (LON:GSK) in a report published on Wednesday morning, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the stock.
Several other analysts have also recently commented on GSK. Shore Capital reaffirmed a hold rating on shares of GlaxoSmithKline plc in a research note on Friday, April 21st. Deutsche Bank AG reaffirmed a hold rating and issued a GBX 1,720 ($22.41) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, April 12th. J P Morgan Chase & Co reaffirmed a neutral rating on shares of GlaxoSmithKline plc in a research note on Monday, July 24th. BNP Paribas reaffirmed an underperform rating and issued a GBX 1,520 ($19.80) target price on shares of GlaxoSmithKline plc in a research note on Monday, April 3rd. Finally, Liberum Capital reaffirmed a buy rating and issued a GBX 1,900 ($24.75) target price on shares of GlaxoSmithKline plc in a research note on Thursday, March 30th. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company. GlaxoSmithKline plc has an average rating of Hold and an average price target of GBX 1,734.73 ($22.60).
Shares of GlaxoSmithKline plc (LON GSK) opened at 1518.50 on Wednesday. The stock has a 50 day moving average price of GBX 1,638.77 and a 200-day moving average price of GBX 1,627.17. GlaxoSmithKline plc has a 52-week low of GBX 1,446.50 and a 52-week high of GBX 1,745.56. The stock’s market capitalization is GBX 74.22 billion.
WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/ubs-ag-reiterates-gbx-1600-price-target-for-glaxosmithkline-plc-gsk/1462263.html.
The firm also recently announced a dividend, which will be paid on Thursday, October 12th. Investors of record on Thursday, August 10th will be issued a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.23%.
In other news, insider Patrick Vallance acquired 861 shares of the business’s stock in a transaction on Friday, July 14th. The shares were purchased at an average price of GBX 1,618 ($21.08) per share, for a total transaction of £13,930.98 ($18,148.75). Also, insider Victoria Whyte sold 4,820 shares of the business’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of GBX 1,693 ($22.06), for a total transaction of £81,602.60 ($106,308.75). Insiders have purchased a total of 3,150 shares of company stock worth $5,054,075 in the last 90 days.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.